LMR Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

LMR Partners’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,133,181	Closed	-$46.3M	–	1665
2024 Q2	$46.3M	Buy	1,133,181 +207,063	+22%	+$8.62M	0.39%	46
2024 Q1	$39.1M	Buy	926,118 +601,535	+185%	+$25.3M	0.4%	53
2023 Q4	$13.8M	Buy	+324,583	New	+$9.33M	0.16%	157
2021 Q4	–	Sell	-50,000	Closed	-$1.48M	–	1314
2021 Q3	$1.48M	Buy	+50,000	New	+$1.4M	0.02%	538
2021 Q2	–	Sell	-22,145	Closed	-$304K	–	1369
2021 Q1	$304K	Buy	+22,145	New	+$324K	0.01%	731

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

LMR Partners's CERE Position: Q3 2024 in Review

LMR Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,133,181 shares — an estimated $46.3M sold.

LMR Partners first reported a position in CERE in Q1 2021 and held it in 5 quarters. The position peaked at $46.3M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

LMR Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
LMR Partners sold 1,133,181 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $46.3M.
LMR Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
LMR Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $46.3M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.